There is a considerable risk of mechanical failure with Bjork-Shiley convexo-concave (BScc) heart valves.l To avert this risk prophylactic replacement of a BScc valve may be considered. We aimed to develop a simple tool to quantify the gain or loss of life-expectancy if a BScc valve were to be replaced and hence aid decision-making in individual patients. Moreover, it should help the clinician to assess the impact on various subgroups of patients of the recent and forthcoming revisions of the estimates of fracture risks.
BScc heart valves were withdrawn from the market in 1986 after reports of mechanical failure (outlet strut fracture). Estimates Recently published revised estimates of fracture risk56 include production characteristics such as weld date (five periods for 600 aortic valves and six periods for 600 mitral valves), welder (group A, B, or C for 600 valves), and remilling status (for 700 valves). Other valve characteristics are site of implantation (aortic/mitral), size, and opening angle (600/700). Basal life-expectancy (years)
A graph (figure) forms the central element of the decision support tool. It shows the loss of life-expectancy caused by fracture in relation Prophylactic replacement ofBjdrk-Shiley convexo-concave heart valves: an easy-to-use tool to aid decision-making in individual patients the fracture risk and the lethality of fracture: 0-35 x 51% = 0-18% per year. Finally, we use the graph (figure) to determine the loss of life-expectancy caused by fracture. Our hypothetical patient with a basal life-expectancy of 25 years and a lethal fracture risk of 0<18% per year, has an estimated loss of around 2-7%.
Comparison of the loss of life-expectancy (2 7%) caused by fracture with the surgical mortality (0-9%) reveals that replacement of this particular BScc valve would improve lifeexpectancy in this patient. The magnitude of this difference in years is calculated by multiplying the relative losses and the basal lifeexpectancy. The expected number of years lost owing to surgery is 0-9% x 25 = 0.23 year, while the loss caused by strut fracture would be 2-7% x 25 = 0-68 year. The advantage of surgery is relatively small: 0-68 -0-23 = 0-45 year.
The graph can be used to evaluate one patient at a time. To evaluate groups of patients, we derived formulas (presented in the Appendix) that can be easily applied by using a computer. For example, we used a spreadsheet program to assess the consequences of revisions of fracture risk for the BScc patients in our centre. We evaluated the patients by using their actual age, gender, and sex-specific weight, but we optimistically assumed that no comorbidity was present. Subsequently, we performed a more detailed and individualised examination of those patients for whom there was a calculated benefit of replacement.
Discussion
We present an easy-to-use tool to estimate the life-expectancy of replacement or of observation for patients with a BScc valve. This tool presents the output of a previously developed decision analysis model9 in such a way that newly available fracture risk estimates and surgical risk estimates can be easily included in decision-making in individual patients as well as in groups of patients.
Selection of candidates for replacement can be based on the estimated risk of fracture, with a closer examination of patients with valves associated with a relatively high risk.5 The impact of a certain fracture risk, however, depends on individual patient characteristics, especially age, because a higher age both increases surgical risk and diminishes lifeexpectancy. For example, Blackstone and Kirklin"2 considered two hypothetical female patients of 38 and 67 years old, without comorbidity, with a fracture risk of 2% in a BScc mitral valve, and a lethality of fracture of 50%. Their analysis indicated that the advantage of surgery in the 67 old patient was minimal, and that the advantage in the 38 year old patient was somewhat larger. Our decision tool confirms these findings qualitatively, but indicates that the magnitude of the advantage of replacement in the 38 year old female patient (assuming NYHA class 1, first reoperation, 60 kg) is as large as 4-3 years, which strongly supports replacement. We propose that the selection of patients for replacement should use this expected benefit as the starting point. This benefit can easily be calculated with our decision tool, either by hand (figure) or by computer (formulas in Appendix).
There can be considerable uncertainty about the true values of estimates required for decision-making in patients with BScc valves. The advantage of our tool is that the impact of variations in estimates can be explored directly. If, for example, the estimated fracture risk is varied to the extremes of a wide but plausible range, the loss of life-expectancy corresponding to these extremes is directly available. Uncertainty in the estimates of fracture risks is caused firstly by underreporting, which leads to a systematic bias both in the reported fracture risks and the lethality of fracture. Underreporting may be a particular problem in aortic BScc valves, because patients who have a strut fracture usually die within two hours,3 without distinct symptoms of mechanical failure. Secondly, the estimates of strut fracture risks are uncertain because of the limited number of fractures available for multivariate statistical analysis. Estimates of surgical mortality were taken from a large recently published series,'0 but may vary because of centre-specific circumstances or the presence of risk factors not considered in the model. The predicted mortalities in table 2 are probably rather optimistic for generalisation to all surgeons in all centres with less experience in valve replacement. Clinical judgment may therefore be required for the final estimation of surgical mortality. In addition, estimates of basal life-expectancy may be lower than the figures in table 2,3 for example because of the presence of risk factors that have not been considered."3 Further, the lethality of fracture may vary because of the patient's age, clinical condition, feasibility of urgent surgery, and time to reach medical facilities for urgent surgery. The effect of these uncertainties can be quantified directly by our method.
This analysis did not consider decisionmaking in patients undergoing bypass surgery or in patients with aortic as well as mitral BScc valves, because no reliable data on basal lifeexpectancy and surgical mortality were available for these types of patients. The approach is, however, identical to the approach followed in patients who are considered for elective replacement of one BScc valve, without concomitant bypass surgery. Again the surgical risk has to be weighed against the cumulative risk of fracture. In patients undergoing bypass surgery, surgical mortality refers to the additional risk of valve surgery compared with bypass surgery alone, and basal life-expectancy refers to the life-expectancy after successful bypass surgery. In patients with two BScc valves, surgical mortality associated with replacement of the aortic, the mitral, or both valves has to be weighed against the cumulative risk of fracture of the aortic, the mitral, or both valves respectively.
Decision-making in patients with BScc valves is difficult because the risks of strut fracture are relatively low, whereas replacement 
